Citations

Clear

2438 citation(s) found for "Ly, Amy".

Building Authentic Connection in the Patient-Physician Relationship
Fuehrer, Sheryl, Weil, Amy , Osterberg, Lars , Meunier, Matthew R. , Schwartz, Rachel , Schwartz, Rachel , Zulman, Donna M.

Mayo Clinic

Journal of Primary Care & Community Health | January 28, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319231225996 | PMID 38281122 Get It

Introduction/Objectives: Delivering optimal patient care is impacted by a physician’s ability to build trusting relationships with patients. Identifying techniques for rapport building is important for promoting patient-physician collaboration and improved patient outcomes. This study sought to characterize the approaches highly skilled primary care physicians (PCPs) use to effectively connect with diverse patients. Methods: Using an inductive thematic analysis approach, we analyzed semi-structured interview transcripts with 10 PCPs identified by leadership and/or colleagues for having exceptional patient communication skills. PCPs practiced in 3 diverse clinic settings: (1) academic medical center, (2) Veterans Affairs clinic, and (3) safety-net community clinic. Results and Conclusions: The thematic analysis yielded 5 themes that enable physicians to establish connections with patients: Respect for the Patient, Engaged Curiosity, Focused Listening, Mutual Participation, and Self-Awareness. Underlying all of these themes was a quality of authenticity, or a state of symmetry between one’s internal experience and external words and actions. Adopting these communication techniques while allowing for adaptability in order to remain authentic in one’s interactions with patients may facilitate improved connection and trust with patients. Encouraging physician authenticity in the patient-physician relationship supports a shift toward relationship-centered care. Additional medical education training is needed to facilitate authentic connection between physicians and patients.
Idiopathic Granulomatous Mastitis
Dilaveri, Christina A. , Lee, Christine U. , Moldoveanu, Dan , Ghosh, Karthik, Dilaveri, Christina , Degnim, Amy, DeSimone, Daniel, Degnim, Amy C. , DeSimone, Daniel C.

Mayo Clinic

The Breast Journal | January 25, 2024 | Volume: 2024 | Issue: No issue available | Pages: 1-9

10.1155/2024/6693720 | PMID 38304866 Get It

Idiopathic granulomatous mastitis (IGM) is a rare, benign inflammatory disorder of the breast that is often underrecognized. The exact etiology and pathophysiology are unknown, but milk stasis is felt to play a role. Classically, this condition is noninfectious, but many cases are noted to be associated with Corynebacterium species. Most patients affected are parous women with a mean age of 35, and many have breastfed within five years of diagnosis. Patients typically present with a painful mass and symptoms of inflammation, and these features can sometimes mimic breast cancer. Biopsy is needed to make a definitive diagnosis, and noncaseating granulomas are found on core biopsy. Many patients have a waxing and waning course over a period of six months to two years. Goal of treatment is to avoid surgery given poor wound healing, high risk of recurrence, and poor cosmetic outcomes. Medical treatment is preferred and includes observation, antibiotics, steroids, and immune modulators such as methotrexate. In more recent years, topical and intralesional steroids have become the treatment of choice, with similar outcomes to oral steroids.
Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020
Davidson, Tara M. , Glasgow, Amy E. , Yan, Yiyi, Hieken, Tina J. , Habermann, Elizabeth B.

Mayo Clinic

Melanoma Research | January 24, 2024 | Volume: 34 | Issue: 2 | Pages: 175-181

10.1097/cmr.0000000000000953 | PMID 38265469 Get It

Melanoma diagnosed within 1 year of pregnancy is defined as pregnancy-associated melanoma (PAM). No robust data on how pregnancy influences melanoma nor guidelines for PAM management exist. With IRB approval, female patients with a pathology-confirmed melanoma diagnosis within 1 year of pregnancy treated at our institution from 2000 to 2020 were identified. Controls from the cancer registry were matched 1 : 4 when available on decade of age, year of surgery (±5), and stage. We identified 83 PAM patients with median follow-up of 86 months. Mean age at diagnosis was 31 years. 80% AJCC V8 stage I, 2.4% stage II, 13% stage III, 4.8% stage IV. Mean Breslow thickness was 0.79 mm and 3.6% exhibited ulceration. The mean mitotic rate was 0.76/mm 2 . In terms of PAM management, 98.6% of ESD patients and 86.7% of LSD patients received standard-of-care therapy per NCCN guidelines for their disease stage. No clinically significant delays in treatment were noted. Time to treatment from diagnosis to systemic therapy for LSD patients was an average of 46 days (95% CI: 34–59 days). Comparing the 83 PAM patients to 309 controls matched on age, stage, and year of diagnosis, similar 5-year overall survival (97% vs. 97%, P = 0.95) or recurrence-free survival (96% vs. 96%, P = 0.86) was observed. The outcomes of PAM following SOC treatment at a highly specialized center for melanoma care were comparable to non-PAM when matched by clinical-pathologic features. Specialty center care is encouraged for women with PAM.
Submucosal Epstein-Barr Virus Positive Polymorphic B-cell Lymphoproliferative Disorder of the Larynx: A Case Report
Mumtaz, Sehreen , Candelo, Estephanía , Krishna, Murli , Jiang, Liuyan , Bhatt, Alok A. , Bridges, Margaret, Cardona-Cardona, Andrés Felipe , Rutt, Amy L. , Berianu, Florentina , Butendieck, Ronald R., Cardona, Andres , Rutt, Amy L. , Gomez, Estephania Candelo , Bhatt, Alok A , Mumtaz, Sehreen , Bridges, Margaret

Mayo Clinic

Ear, Nose & Throat Journal | January 24, 2024 | Volume: 105 | Issue: 8 | Pages: No page available

10.1177/01455613231226017 | PMID 38264837 Get It

Epstein-Barr virus (EBV) belongs to the group of human herpes virus and can cause clinical and subclinical infections. Although EBV-related disease presentations are similar, they can lead to oncogenic transformation with various clinical manifestations. A thorough workup with morphology, immunohistochemistry, and molecular studies is crucial for the diagnosis of EBV-positive polymorphic B-cell lymphoproliferative disorder, not otherwise specified (NOS), which is a new entity introduced by International Consensus Classification in 2022. We describe an interesting presentation of EBV-positive polymorphic B-cell lymphoproliferative disorder with laryngeal involvement to bring awareness to this entity and we would like to address the need for more accessible treatment options.
Epidemiologic Factors in Relation to Colorectal Cancer Risk and Survival by Genotoxic Colibactin Mutational Signature
Thomas, Claire E. , Georgeson, Peter , Qu, Conghui , Steinfelder, Robert S. , Buchanan, Daniel D. , Song, Mingyang , Harrison, Tabitha A. , Um, Caroline Y. , Hullar, Meredith A.J. , Guelpen, Bethany Van , Huyghe, Jeroen R. , Aglago, Elom K. , Berndt, Sonja I. , Drew, David A. , Figueiredo, Jane C. , French, Amy J. , Giannakis, Marios , Goode, Ellen L. , Gruber, Stephen B. , Gsur, Andrea , Hoffmeister, Michael , Huang, Wen‐Yi , Newton, Christina C. , Obón‐Santacana, Mireia , Zaidi, Syed Hassan Ejaz , Peters, Ulrike , Phipps, Amanda I. , Hullar, Meredith A , Jenkins, Mark A , Van Guelpen, Bethany , Lynch, Brigid M , Melaku, Yohannes Adama , Huyghe, Jeroen R , Aglago, Elom K , Berndt, Sonja I , Boardman, Lisa , Campbell, Peter T , Cao, Yin , Chan, Andrew T , Drew, David A , Figueiredo, Jane C , Giannakis, Marios , Goode, Ellen L , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Hoffmeister, Michael , Hsu, Li , Huang, Wen-Yi , Moreno, Victor , Murphy, Neil , Newcomb, Polly A. , Newton, Christina C , Nowak, Jonathan A , Obón-Santacana, Mireia , Ogino, Shuji , Sun, Wei , Toland, Amanda Ewart , Trinh, Quang M , Ugai, Tomotaka , Zaidi, Syed H , Peters, Ulrike , Phipps, Amanda I , Buchanan, Daniel D , Harrison, Tabitha A , Um, Caroline Y , Song, Mingyang , Georgeson, Peter , Qu, Conghui , Steinfelder, Robert S , Thomas, Claire E , Jenkins, Mark A. , Boardman, Lisa A. , Campbell, Peter T. , Cao, Yin , Chan, Andrew T. , Gunter, Marc J. , Moreno, Vı́ctor , Murphy, Neil , Nowak, Jonathan A. , Sun, Wei , Trinh, Quang M.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 22, 2024 | Volume: 33 | Issue: 4 | Pages: 534-546

10.1158/1055-9965.epi-23-0600 | PMID 38252034 Get It

Abstract Background: The genotoxin colibactin causes a tumor single-base substitution (SBS) mutational signature, SBS88. It is unknown whether epidemiologic factors’ association with colorectal cancer risk and survival differs by SBS88. Methods: Within the Genetic Epidemiology of Colorectal Cancer Consortium and Colon Cancer Family Registry, we measured SBS88 in 4,308 microsatellite stable/microsatellite instability low tumors. Associations of epidemiologic factors with colorectal cancer risk by SBS88 were assessed using multinomial regression (N = 4,308 cases, 14,192 controls; cohort-only cases N = 1,911), and with colorectal cancer–specific survival using Cox proportional hazards regression (N = 3,465 cases). Results: 392 (9%) tumors were SBS88 positive. Among all cases, the highest quartile of fruit intake was associated with lower risk of SBS88-positive colorectal cancer than SBS88-negative colorectal cancer [odds ratio (OR) = 0.53, 95% confidence interval (CI) 0.37-0.76; OR = 0.75, 95% CI 0.66–0.85, respectively, Pheterogeneity = 0.047]. Among cohort studies, associations of body mass index (BMI), alcohol, and fruit intake with colorectal cancer risk differed by SBS88. BMI ≥30 kg/m2 was associated with worse colorectal cancer–specific survival among those SBS88-positive [hazard ratio (HR) = 3.40, 95% CI 1.47–7.84], but not among those SBS88-negative (HR = 0.97, 95% CI 0.78–1.21, Pheterogeneity = 0.066). Conclusions: Most epidemiologic factors did not differ by SBS88 for colorectal cancer risk or survival. Higher BMI may be associated with worse colorectal cancer–specific survival among those SBS88-positive; however, validation is needed in samples with whole-genome or whole-exome sequencing available. Impact: This study highlights the importance of identification of tumor phenotypes related to colorectal cancer and understanding potential heterogeneity for risk and survival.
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination
Cynthia, X. , Sanati, Souzan , Leitch, A. Marilyn , Unzeitig, Gary, Fernández-Martínez, Aranzazu , Fan, Cheng , Gibbs, Richard A. , Dockter, Travis , Hahn, Olwen, Guenther, Joseph M., Caudle, Abigail S. , Crouch, Erika C., Tiersten, Amy , Mita, Monica , Razaq, Wajeeha, Rimawi, Mothaffar F. , Weiss, Anna , Perou, Charles M. , Carey, Lisa A. , Dockter, Travis J, Carey, Lisa A , Perou, Charles M , Rimawi, Mothaffar , Fernandez-Martinez, Aranzazu , Suman, Vera J. , Vij, Kiran R , Anurag, Meenakshi , Hoog, Jeremy , Watson, Mark A. , Hieken, Tina J. , Wang, Yang , Winer, Eric P. , Hunt, Kelly K. , Ellis, Matthew J. , Partridge, Ann H.

Mayo Clinic

JAMA Oncology | January 18, 2024 | Volume: 10 | Issue: 3 | Pages: 362

10.1001/jamaoncol.2023.6038 | PMID 38236590 Get It

Importance Adding fulvestrant to anastrozole (A+F) improved survival in postmenopausal women with advanced estrogen receptor (ER)–positive/ERBB2 (formerly HER2)–negative breast cancer. However, the combination has not been tested in early-stage disease. Objective To determine whether neoadjuvant fulvestrant or A+F increases the rate of pathologic complete response or ypT1-2N0/N1mic/Ki67 2.7% or less residual disease (referred to as endocrine-sensitive disease) over anastrozole alone. Design, Setting, and Participants A phase 3 randomized clinical trial assessing differences in clinical and correlative outcomes between each of the fulvestrant-containing arms and the anastrozole arm. Postmenopausal women with clinical stage II to III, ER-rich (Allred score 6-8 or >66%)/ERBB2-negative breast cancer were included. All analyses were based on data frozen on March 2, 2023. Interventions Patients received anastrozole, fulvestrant, or a combination for 6 months preoperatively. Tumor Ki67 was assessed at week 4 and optionally at week 12, and if greater than 10% at either time point, the patient switched to neoadjuvant chemotherapy or immediate surgery. Main Outcomes and Measures The primary outcome was the endocrine-sensitive disease rate (ESDR). A secondary outcome was the percentage change in Ki67 after 4 weeks of neoadjuvant endocrine therapy (NET) (week 4 Ki67 suppression). Results Between February 2014 and November 2018, 1362 female patients (mean [SD] age, 65.0 [8.2] years) were enrolled. Among the 1298 evaluable patients, ESDRs were 18.7% (95% CI, 15.1%-22.7%), 22.8% (95% CI, 18.9%-27.1%), and 20.5% (95% CI, 16.8%-24.6%) with anastrozole, fulvestrant, and A+F, respectively. Compared to anastrozole, neither fulvestrant-containing regimen significantly improved ESDR or week 4 Ki67 suppression. The rate of week 4 or week 12 Ki67 greater than 10% was 25.1%, 24.2%, and 15.7% with anastrozole, fulvestrant, and A+F, respectively. Pathologic complete response/residual cancer burden class I occurred in 8 of 167 patients and 17 of 167 patients, respectively (15.0%; 95% CI, 9.9%-21.3%), after switching to neoadjuvant chemotherapy due to week 4 or week 12 Ki67 greater than 10%. PAM50 subtyping derived from RNA sequencing of baseline biopsies available for 753 patients (58%) identified 394 luminal A, 304 luminal B, and 55 nonluminal tumors. A+F led to a greater week 4 Ki67 suppression than anastrozole alone in luminal B tumors (median [IQR], −90.4% [−95.2 to −81.9%] vs −76.7% [−89.0 to −55.6%]; P < .001), but not luminal A tumors. Thirty-six nonluminal tumors (65.5%) had a week 4 or week 12 Ki67 greater than 10%. Conclusions and Relevance In this randomized clinical trial, neither fulvestrant nor A+F significantly improved the 6-month ESDR over anastrozole in ER-rich/ERBB2-negative breast cancer. Aromatase inhibition remains the standard-of-care NET. Differential NET response by PAM50 subtype in exploratory analyses warrants further investigation. Trial Registration ClinicalTrials.gov Identifier: NCT01953588
Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer
Jahangir, Chowdhury Arif , Page, David B. , Broeckx, Glenn , Gonzalez, Claudia Aura, Burke, Caoimbhe, Murphy, Clodagh, Reis‐Filho, Jorge S. , Gupta, Rajarsi , Vieth, Michael, Hida, Akira I. , Kahila, Mohamed M. , Kos, Zuzana , Verbandt, Sara , Thagaard, Jeppe , Khiroya, Reena, Haab, Gabriela Acosta , Ács, Balázs , Alvarado‐Cabrero, Isabel , Baharun, Nurkhairul Bariyah, Bellolio, Enrique , Bheemaraju, Vydehi, Blenman, Kim RM, Fujimoto, Luciana Botinelly Mendonça , Burgues, Octavio, Cheang, Maggie C.U. , Ciompi, Francesco , Cooper, Lee , Coosemans, An , Corredor, Germán, Portela, Flávio Luis Dantas , Deman, Frederik , Dudgeon, Sarah , Elghazawy, Mahmoud , Fernandez‐Martín, Claudio , Fineberg, Susan , Gnjatic, Sacha , Halama, Niels , Hanna, Matthew G, Harbhajanka, Aparna , Hartman, Johan , Hewitt, Stephen M. , Husain, Zaheed, Irshad, Sheeba , Kataoka, Tatsuki R. , Kawaguchi, Kosuke, Khramtsov, Andrey , Kirtani, Pawan , Korski, Konstanty, Scott, Ely, Lænkholm, Anne‐Vibeke , Lang‐Schwarz, Corinna , Larsimont, Denis , Lennerz, Jochen K. , Li, Xiaoxian , Maley, Sai, Narasimhamurthy, Vidya Manur, Marks, Douglas K. , Mehrotra, Ravi , Durga, Kharidehal, Mittal, Shachi , Mushtaq, Shamim , Hussain, Nighat , Papathomas, Thomas , Perera, Rashindrie , Pinard, Christopher J. , Pinto‐Cardenas, Juan Carlos , Rau, Tilman T. , Ribeiro, Joana , Hytopoulos, Evangelos, Mahon, Sarah, Siziopikou, Kalliopi P. , Sotiriou, Christos, Stenzinger, Albrecht , Symmans, Fraser, Tanaka, Sunao , Taxter, Timothy , Tejpar, Sabine , Thompson, E. Aubrey , Tramm, Trine , Tran, William T, Verghese, Gregory , Viale, Giuseppe , Wahab, Noorul , Walter, Thomas , Waumans, Yannick , Wen, Hannah Y. , Yang, Wentao , Bartlett, John M.S. , Loibl, Sibylle , Loi, Sherene , Stovgaard, Elisabeth Specht , Salgado, Roberto , Gupta, Rajarsi R , Chardas, Alexandros , Dantas Portela, Flavio Luis , Elghazawy, Mahmoud , Gonzalez-Ericsson, Paula I , Grigoriadis, Anita , Hart, Steven N , Hartman, Johan , Kataoka, Tatsuki R , Rau, Tilman T , Rimm, David , Verghese, Gregory E , Wahab, Noorul , Gnjatic, Sacha , Broeckx, Glenn , Cheang, Maggie Chon U , Lennerz, Jochen , Loi, Sherene , Reis-Filho, Jorge S , Acs, Balazs , Walter, Thomas , Irshad, Sheeba , McDonald, Elizabeth S. , Ly, Amy , Harms, Paul W. , Diest, P. J. van , AbdulJabbar, Khalid , Adams, Sylvia , Almeida, Jonas S. , Ardalan, Farid Azmoudeh , Badve, Sunil , Hardas, Alexandros , Corredor, Germán , Demaria, Sandra , Fox, Stephen B. , Giltnane, Jennifer Margaret , González-Ericsson, Paula I. , Hart, Steven N. , Horlings, Hugo , Janssen, Emiel A. M. , Kawaguchi, Kosuke , Kiraz, Umay , Kodach, Liudmila L. , Aktürk, Güray , Kovács, Anikó , Lerousseau, Marvin , Madabhushi, Anant , Michiels, Stefan , Minhas, Fayyaz , Moore, David , Penault-Llorca, Frederique Madeleine , Pruneri, Giancarlo , Pusztai, Lajos , Rajpoot, Nasir , Rapoport, Bernardo L. , Rimm, David L. , Vincent‐Salomon, Anne , Saltz, Joel , Sayed, Shahin , Sughayer, Maher A. , Sur, Daniel Genel , Symmans, W. Fraser , Teuwen, Jonas , Tran, William T, Laak, Jeroen van der , Yuan, Yinyin , Denkert, Carsten , Savas, Peter Stephen , Gallagher, William M. , Rahman, Arman

Mayo Clinic

The Journal of Pathology | January 17, 2024 | Volume: 262 | Issue: 3 | Pages: 271-288

10.1002/path.6238 | PMID 38230434 Get It

Abstract Recent advances in the field of immuno‐oncology have brought transformative changes in the management of cancer patients. The immune profile of tumours has been found to have key value in predicting disease prognosis and treatment response in various cancers. Multiplex immunohistochemistry and immunofluorescence have emerged as potent tools for the simultaneous detection of multiple protein biomarkers in a single tissue section, thereby expanding opportunities for molecular and immune profiling while preserving tissue samples. By establishing the phenotype of individual tumour cells when distributed within a mixed cell population, the identification of clinically relevant biomarkers with high‐throughput multiplex immunophenotyping of tumour samples has great potential to guide appropriate treatment choices. Moreover, the emergence of novel multi‐marker imaging approaches can now provide unprecedented insights into the tumour microenvironment, including the potential interplay between various cell types. However, there are significant challenges to widespread integration of these technologies in daily research and clinical practice. This review addresses the challenges and potential solutions within a structured framework of action from a regulatory and clinical trial perspective. New developments within the field of immunophenotyping using multiplexed tissue imaging platforms and associated digital pathology are also described, with a specific focus on translational implications across different subtypes of cancer. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Assessing cardiovascular disease risk in women with a history of hypertensive disorders of pregnancy: A guidance paper for studies using administrative data
Johnston, Amy , Smith, Graeme N. , Coutinho, Thais , Smith, Graeme N , Tanuseputro, Peter , Edwards, Jodi D.

Mayo Clinic

Paediatric and Perinatal Epidemiology | January 15, 2024 | Volume: 38 | Issue: 3 | Pages: 254-267

10.1111/ppe.13043 | PMID 38220144 Get It

AbstractBackgroundHypertensive disorders of pregnancy (HDP) are a major cause of maternal morbidity and mortality, and their association with increased cardiovascular disease (CVD) risk represents a major public health concern. However, assessing CVD risk in women with a history of these conditions presents unique challenges, especially when studies are carried out using routinely collected data.ObjectivesTo summarise and describe key challenges related to the design and conduct of administrative studies assessing CVD risk in women with a history of HDP and provide concrete recommendations for addressing them in future research.MethodsThis is a methodological guidance paper.ResultsSeveral conceptual and methodological factors related to the data‐generating mechanism and study conceptualisation, design/data management and analysis, as well as the interpretation and reporting of study findings should be considered and addressed when designing and carrying out administrative studies on this topic. Researchers should develop an a priori conceptual framework within which the research question is articulated, important study variables are identified and their interrelationships are carefully considered.ConclusionsTo advance our understanding of CVD risk in women with a history of HDP, future studies should carefully consider and address the conceptual and methodological considerations outlined in this guidance paper. In highlighting these challenges, and providing specific recommendations for how to address them, our goal is to improve the quality of research carried out on this topic.
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes
Cerhan, James R. , Maurer, Matthew J. , Link, Brian K. , Feldman, Andrew L. , Habermann, Thomas M. , Jaye, David L. , Burack, Richard , McDonnell, Timothy J. , Vega, Francisco , Chapman, Jennifer R. , Leonard, John P. , Bernal‐Mizrachi, Leon , Alderuccio, Juan Pablo , Riska, Shaun M., Gysbers, Brianna, Lunde, Julianne J. , Reicks, Tanner W., Ayers, Amy , O’Leary, Colin B. , Yost, Kathleen J. , Nowakowski, Grzegorz S. , Ruan, Jia , Koff, Jean L. , Thompson, Carrie A. , Cohen, Jonathon B. , Lossos, Izidore S. , Friedberg, Jonathan W. , Martin, Peter W., Flowers, Christopher R. , Burack, W Richard , Syrbu, Sergei , Vij, Kiran R , Bernal-Mizrachi, Leon , Witzig, T.E. , Weiner, George , Wang, Yucai , Alderuccio, Juan Pablo , Slager, Susan L , Liu, Hongfang , Chihara, Dai , Koff, Jean L , Casulo, Carla , Thompson, Carrie A , Cohen, Jonathon B , Kahl, Brad S , Lossos, Izidore S , Feldman, Andrew L , Maurer, Matthew , Cerhan, James R , Vega, Francisco , Link, Brian K , Habermann, Thomas , Jaye, David L , Syrbu, Sergei , Inghirami, Giorgio , Farooq, Umar , Witzig, Thomas E. , Weiner, George J. , Wang, Yucai , Slager, Susan L. , Larson, Melissa C. , Liu, Hongfang , Chihara, Dai , Casulo, Carla , Kahl, Brad S. , Nastoupil, Loretta J. , Martin, Peter

Mayo Clinic

American Journal of Hematology | January 13, 2024 | Volume: 99 | Issue: 3 | Pages: 408-421

10.1002/ajh.27202 | PMID 38217361 Get It

AbstractTo address the current and long‐term unmet health needs of the growing population of non‐Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/). A total of 7735 newly diagnosed patients aged 18 years and older with NHL were prospectively enrolled from 7/1/2015 to 5/31/2020 at 8 academic centers in the United States. The median age at diagnosis was 62 years (range, 18–99). Participants came from 49 US states and included 538 Black/African‐Americans (AA), 822 Hispanics (regardless of race), 3386 women, 716 age <40 years, and 1513 rural residents. At study baseline, we abstracted clinical, pathology, and treatment data; banked serum/plasma (N = 5883, 76.0%) and germline DNA (N = 5465, 70.7%); constructed tissue microarrays for four major NHL subtypes (N = 1189); and collected quality of life (N = 5281, 68.3%) and epidemiologic risk factor (N = 4489, 58.0%) data. Through August 2022, there were 1492 deaths. Compared to population‐based SEER data (2015–2019), LEO participants had a similar distribution of gender, AA race, Hispanic ethnicity, and NHL subtype, while LEO was underrepresented for patients who were Asian and aged 80 years and above. Observed overall survival rates for LEO at 1 and 2 years were similar to population‐based SEER rates for indolent B‐cell (follicular and marginal zone) and T‐cell lymphomas, but were 10%–15% higher than SEER rates for aggressive B‐cell subtypes (diffuse large B‐cell and mantle cell). The LEO cohort is a robust and comprehensive national resource to address the role of clinical, tumor, host genetic, epidemiologic, and other biologic factors in NHL prognosis and survivorship.
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
Woyach, Jennifer A. , Burbano, Gabriela Perez , Ruppert, Amy S. , Heerema, Nyla A. , Zhao, Weiqiang , Wall, Anna, Brander, Danielle M. , Rogers, Kerry A. , Stephens, Deborah M. , Brown, Jennifer R. , Lozanski, Gerard , Nattam, Sreenivasa, Litzow, Mark R. , Luger, Selina M. , Owen, Carolyn , Kuzma, Charles, Little, Richard F. , Dinner, Shira, Stone, Richard M. , Uy, Geoffrey L. , Mandrekar, Sumithra J. , Byrd, John C. , Perez Burbano, Gabriela , Barr, Paul M , Rogers, Kerry A , Parikh, Sameer A , Stephens, Deborah M , Blachly, James , Larson, Richard A , Erba, Harry Paul , Litzow, Mark R. , Abramson, Jeremy S , Little, Richard F , Uy, Geoffrey , Byrd, John C , Miller, Cecelia , Ding, Wei , Bartlett, Nancy L. , Barr, Paul M. , Parikh, Sameer A. , Blachly, James S. , Larson, Richard A. , Abramson, Jeremy S. , Stock, Wendy

Mayo Clinic

Blood | January 12, 2024 | Volume: 143 | Issue: 16 | Pages: 1616-1627

10.1182/blood.2023021959 | PMID 38215395 Get It

Abstract A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR) in previously untreated older patients with chronic lymphocytic leukemia (CLL). The initial results showed that ibrutinib-containing regimens had superior progression-free survival (PFS) and rituximab did not add additional benefits. Here we present an updated analysis. With a median follow-up of 55 months, the median PFS was 44 months (95% confidence interval [CI], 38-54) for BR and not yet reached in either ibrutinib-containing arm. The 48-month PFS estimates were 47%, 76%, and 76% for BR, ibrutinib, and IR, respectively. The benefit of ibrutinib regimens over chemoimmunotherapy was consistent across subgroups of patients defined by TP53 abnormalities, del(11q), complex karyotype, and immunoglobulin heavy chain variable region (IGHV). No significant interaction effects were observed between the treatment arm and del(11q), the complex karyotype, or IGHV. However, a greater difference in PFS was observed among the patients with TP53 abnormalities. There was no difference in the overall survival. Notable adverse events with ibrutinib included atrial fibrillation (afib) and hypertension. Afib was observed in 11 patients (pts) on BR (3%) and 67 pts on ibrutinib (18%). All-grade hypertension was observed in 95 pts on BR (27%) and 263 pts on ibrutinib (55%). These data show that ibrutinib regimens prolong PFS compared with BR for older patients with treatment-naïve CLL. These benefits were observed across subgroups, including high-risk groups. Strikingly, within the ibrutinib arms, there was no inferior PFS for patients with abnormalities in TP53, the highest risk feature observed in CLL. These data continue to demonstrate the efficacy of ibrutinib in treatment-naïve CLL.